ZEISS MyoCare lenses
A better outlook on life.
Our most effective lens designs aimed to slow myopia progression. MyoCare is backed by ZEISS innovation and more than a decade of experience in developing lenses to manage myopia progression.
ZEISS MyoCare lenses
Recommended for children younger than 10 years. Incorporating
I) Cylindrical Annular Refractive Elements, C.A.R.E.® technology – aimed to deliver a “stop signal” to slow down progression of axial elongation. It consists of alternating defocus and correction zones in a ring-like pattern on the front surface, expanding towards the periphery of the lens. (Please note that the image above is an exaggerated animation and not a real image.)
II) ZEISS ClearFocus design – aimed to remove the “growth signal”, the optimised back surface delivers the refractive correction as well as intended myopic defocus of the patient for all gaze directions.
- Central clear zone of 7 mm
- Mean additional surface power of +4.6 D
- Fill factor of 0.5
Myopia is a growing concern worldwide
One problem – many solutions.
Optical, medical and behavioural treatments.
Because of its multifactorial causes, there's no one-and-only treatment for myopia. In fact, there are many treatment options on the market including optical, medical and behavioural treatments.
The choice of myopia treatments for children should be based on the age of onset, and axial length or refraction at a given age, along with knowledge of their individual rate of progression and overall risk profile. Comprehensive myopia treatments include a combination of lifestyle advice, a refractive correction method for full-time use, and myopia control methods to reduce or eliminate further progression.
A new lens design.
Creating simultaneous competing defocus.
Our latest lens designed to manage progressive myopia in children, is built on more than a decade of ZEISS innovation and experience in myopia management, in collaboration with optical experts such as material and vision scientists, eye care practitioners and academics. The design of ZEISS MyoCare lenses incorporates scientific concepts from proven scientific research, evidence-based learnings and effective treatments, including orthokeratology, soft multifocal contact lenses, science and the new generation of spectacles.
Finding the right balance.
The perfect combination of distinct optimisation parameters and a specific design.
An effective myopia mangement lens must overcome certain design challenges and find the optimum balance between myopia progression management and good vision. For this we have included the following in our ZEISS myopia management solutions:
- A central zone small enough to establish an effective functional zone projecting myopic defocus on the near periphery close to the fovea
- A mean addition surface power to induce the intended relative myopic defocus
- A carefully selected fill factor to deliver high efficacy while preserving good wearability
ZEISS ClearFocus design.
Addressing the constant movement of the eyes.
Spectacle lenses must consider the moving eye behind the lens to ensure that the intended correction and myopic defocus is maintained for all gaze angles. With the ZEISS ClearFocus design, both the optimal refractive correction according to the patient’s refractive demands and the intended myopic defocus are maintained for all gaze directions. This is important not only for distinct viewing behaviours through the central clear zone when pursuing a focused task, but also for unintended gazes and saccades to the lens periphery.
In addition to that, the ZEISS ClearFocus design effectively minimises the induction of hyperopic defocus as opposed to typical spherical single vision lenses.
A new approach to measure effectiveness.
Emmetropic progression ratio.
Each myopia progression management intervention has its own advantages and disadvantages, however each option pursues a common target: To slow down myopia progression.
Developmental milestones offer important insights into a child's developmental health. Reaching specific milestones at a given age shows a child is developing as expected. A comparison between the normal physiological growth and the patient’s current growth is needed to observe whether there is some type of non-physiological deviation present.
The ZEISS MyoCare shows an average emmetropic progression ratio for axial length with an average of 70% and ZEISS MyoCare S an average of 68%. 4
New age-related myopia management lens solutions
ZEISS MyoCare
Different interventions have different effects. The same goes for the two different designs in the MyoCare portfolio. According to research results, there is a significant group difference in axial length and spherical equivalent refraction change between the untreated group wearing single vision correction and the treatment group wearing ZEISS MyoCare lenses. Based on this it is recommended to have separate designs for separate age groups:
- MyoCare® for children younger than 10 years
Why MyoCare® lenses should be your choice.
Vision as good as with single vision lenses.
MyoCare® portfolio
A better outlook on life.
-
1
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050, Ophthalmology. 2016;123(5):1036–1042.
-
2
Chen M, Wu A, Zhang L, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey. BMC Ophthalmol. 2018;18(1):159. doi: 10.1186/s12886-018-0829-8.
-
3
Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017; 9 5 ( 6 ):551- 5 6 6 . d o i: 10 .1111/ a o s .13 4 0 3.
-
4
Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of spectacle wear with cylindrical annular refractive elements (CARE)
[Conference presentation abstract]. The Association for Research in Vision and OpthalmologyOphthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
EPR for ages 7-12 year old children as sample size for ages 6 and 13 was small. When the entire sample of 6 to 13 years were considered, EPR for ZEISS MyoCare was 71%.
-
5
Two-year prospective, multi-center, double-blind, randomized controlled clinical trial lead by Tianjin Eye Hospital Optometric Center, China, 2022, on 80 myopic children wearing ZEISS MyoCare Rx lenses, 80 myopic children wearing ZEISS MyoCare S Rx lenses and80 Myopic children wearing ZEISS Single Vision lenses. 12-months interim results presented at ARVO 2024.
-
6
Hong Kong Polytechnic University owns granted patents (including Chinese patent: CN103097940) on annular concentric lens for myopia control, which are licensed to Carl Zeiss. Carl Zeiss started in 2021 to develop in collaboration with Wenzhou Medical University the latest cylindrical annular refractive elements technology for spectacle lenses that is used in MyoCare lens designs.